SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?


To: Craig Lacy who wrote (30625)2/17/2002 3:57:39 PM
From: Zeev Hed  Read Replies (3) | Respond to of 99280
 
I would broaden the spectrum to include some broader generics like IDPH, TARO, and maybe QLTI and possibly BLUD, CRA and MLNM as well. I think that AMGN either breaks $56 and then gets to $53.6 or so, or you don't get it at $55 (g), by the way, a break of $53.3 means real big troubles ahead for the sector and a challenge of 400, it is one to watch for "sector health".

Zeev



To: Craig Lacy who wrote (30625)2/17/2002 5:04:46 PM
From: Ibexx  Respond to of 99280
 
I would add IDPH at $55 and MLNM at $20.

JMHO,
Ibexx



To: Craig Lacy who wrote (30625)2/17/2002 6:17:26 PM
From: seminole  Read Replies (1) | Respond to of 99280
 
Everyone has their favorite bio stocks but when all members of an industry
or group are on sale buy the best first.
Buy Phase III and late development drugs first.
The institutions will buy these quality "stories" first, so should you.
Also, I would add a cancer drug stock with a large number of presentations
at AACR(April) and ASCO(May).
These stocks move on press reports at these meetings.